Vikas Singh1, Rodrigo Mendirichaga2, Ignacio Inglessis-Azuaje3, Igor F Palacios3, William W O'Neill4. 1. Structural Heart Diseases, Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. vikas.dr.singh@gmail.com. 2. Cardiovascular Division, Boston Medical Center, Boston University School of Medicine, Boston, MA, USA. 3. Structural Heart Diseases, Division of Cardiology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA. 4. Structural Heart Diseases, Division of Cardiology, Henry Ford Hospital, Detroit, MI, USA.
Abstract
PURPOSE OF REVIEW: The goal of this review is to discuss the effects of Impella (Abiomed, Danvers, MA), to support in the hemodynamics of patients with severe aortic stenosis, and to explore the clinical scenarios in which the use of Impella may be beneficial in this setting. RECENT FINDINGS: The management of patients with severe aortic stenosis who go on to develop left ventricular failure and cardiogenic shock remains an important clinical challenge associated with increased morbidity and mortality. Once considered a relative contraindication, the use of Impella in severe aortic stenosis has now been proven feasible and demonstrated promising results in selected high-risk patients. The use of Impella to provide hemodynamic support maybe considered in patients with aortic stenosis in cardiogenic shock or those with severe left ventricular dysfunction and CAD who require high-risk PCI and or balloon aortic valvuloplasty. Impella is also an attractive option in selected cases of hemodynamic collapse during TAVR.
PURPOSE OF REVIEW: The goal of this review is to discuss the effects of Impella (Abiomed, Danvers, MA), to support in the hemodynamics of patients with severe aortic stenosis, and to explore the clinical scenarios in which the use of Impella may be beneficial in this setting. RECENT FINDINGS: The management of patients with severe aortic stenosis who go on to develop left ventricular failure and cardiogenic shock remains an important clinical challenge associated with increased morbidity and mortality. Once considered a relative contraindication, the use of Impella in severe aortic stenosis has now been proven feasible and demonstrated promising results in selected high-risk patients. The use of Impella to provide hemodynamic support maybe considered in patients with aortic stenosis in cardiogenic shock or those with severe left ventricular dysfunction and CAD who require high-risk PCI and or balloon aortic valvuloplasty. Impella is also an attractive option in selected cases of hemodynamic collapse during TAVR.
Authors: David R Holmes; Michael J Mack; Sanjay Kaul; Arvind Agnihotri; Karen P Alexander; Steven R Bailey; John H Calhoon; Blase A Carabello; Milind Y Desai; Fred H Edwards; Gary S Francis; Timothy J Gardner; A Pieter Kappetein; Jane A Linderbaum; Chirojit Mukherjee; Debabrata Mukherjee; Catherine M Otto; Carlos E Ruiz; Ralph L Sacco; Donnette Smith; James D Thomas; Robert A Harrington; Deepak L Bhatt; Victor A Ferrari; John D Fisher; Mario J Garcia; Timothy J Gardner; Federico Gentile; Michael F Gilson; Adrian F Hernandez; Alice K Jacobs; Sanjay Kaul; Jane A Linderbaum; David J Moliterno; Howard H Weitz Journal: Catheter Cardiovasc Interv Date: 2012-04-19 Impact factor: 2.692
Authors: Stephen Ramee; Saif Anwaruddin; Gautam Kumar; Robert N Piana; Vasilis Babaliaros; Tanveer Rab; Lloyd W Klein Journal: JACC Cardiovasc Interv Date: 2016-12-12 Impact factor: 11.195
Authors: Susheel K Kodali; Mathew R Williams; Craig R Smith; Lars G Svensson; John G Webb; Raj R Makkar; Gregory P Fontana; Todd M Dewey; Vinod H Thourani; Augusto D Pichard; Michael Fischbein; Wilson Y Szeto; Scott Lim; Kevin L Greason; Paul S Teirstein; S Chris Malaisrie; Pamela S Douglas; Rebecca T Hahn; Brian Whisenant; Alan Zajarias; Duolao Wang; Jodi J Akin; William N Anderson; Martin B Leon Journal: N Engl J Med Date: 2012-03-26 Impact factor: 91.245
Authors: David H Adams; Jeffrey J Popma; Michael J Reardon; Steven J Yakubov; Joseph S Coselli; G Michael Deeb; Thomas G Gleason; Maurice Buchbinder; James Hermiller; Neal S Kleiman; Stan Chetcuti; John Heiser; William Merhi; George Zorn; Peter Tadros; Newell Robinson; George Petrossian; G Chad Hughes; J Kevin Harrison; John Conte; Brijeshwar Maini; Mubashir Mumtaz; Sharla Chenoweth; Jae K Oh Journal: N Engl J Med Date: 2014-03-29 Impact factor: 91.245
Authors: F D'Ascenzo; F Conrotto; F Giordana; C Moretti; M D'Amico; S Salizzoni; P Omedè; M La Torre; M Thomas; Z Khawaja; D Hildick-Smith; Gp Ussia; M Barbanti; C Tamburino; John Webb; R B Schnabel; M Seiffert; S Wilde; H Treede; V Gasparetto; M Napodano; G Tarantini; P Presbitero; M Mennuni; M L Rossi; M Gasparini; G Biondi Zoccai; M Lupo; M Rinaldi; F Gaita; S Marra Journal: Int J Cardiol Date: 2013-04-28 Impact factor: 4.164
Authors: Piotr Kübler; Grzegorz Onisk; Maciej Rachwalik; Roman Przybylski; Krzysztof Reczuch; Marcin Protasiewicz Journal: Postepy Kardiol Interwencyjnej Date: 2021-03-27 Impact factor: 1.426